Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Clinical trial NCT01744223 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT01744223
Sponsor: Bellicum Pharmaceuticals
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Lymphoblastic Leukemia Acute Myelogenous Leukemia Lymphoma Myelodysplastic Syndromes

Start date: 2013-03-01
Primary completion: 2019-10-09
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.